Pipeline dossier

NIH & clinical-trial pipeline signals for vTv Therapeutics Inc. (VTVT)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for VTVT, mapped to public ticker VTVT (CIK 0001641489). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingVTVT55% conf

vTv Therapeutics Inc. (VTVT) — PHASE3 primary completion in ~149 days

Upstream (observed)
Clinical trial status (PHASE3) — Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Recent SEC 8-K filings

2026-10-06 — 8-K 5.03,9.01 view ↗
2026-08-06 — 8-K 2.02,9.01 view ↗
2026-06-29 — 8-K 5.07 view ↗
2026-05-13 — 8-K 8.01,9.01 view ↗
2026-05-13 — 8-K 2.02,9.01 view ↗

JSON API for this entity →